Pushing Boundaries in CMT Research Early Stage Biotech Companies’ Evolution and Insights on Therapy
Panel moderated by William Motley · Rapport Therapeutics
A look at biotech’s interest in CMT, the resources facilitating entry into the field, the challenges of raising funds, and the best timing for engaging larger companies or investors. Panelists: Steve O’Connor (Shift Pharmaceuticals), Thomas Neenan (Nanite), Peter Hamley (Samsara Therapeutics), Douglas V. Faller (Oryzon Genomics), Arthur Suckow (formerly DTx Pharma, Novartis) and Sylvain Celanire (Augustine Therapeutics).